Sign In
1 Jun 2010 12:26
ο»Ώ
1 June 2010
Β
Vernalis Results of Annual General Meeting
Β
Resolutions
Β
Vernalis plc announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.
Β
All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.
Β
|
Resolution |
For (including discretionary votes)* |
Against* |
Withheld |
||
|
Ordinary Resolutions (requires 50% majority) |
|||||
|
1. To receive the audited accounts and related reports of the Directors and auditors |
79,947,812 |
99.99 % |
2,131 |
0.01 % |
403 |
|
2. To approve the remuneration report |
79,932,530 |
99.99 % |
10,178 |
0.01 % |
7,638 |
|
3. To re-elect as a Director Mr G M Kennedy |
57,548,081 |
71.98 % |
22,400,189 |
28.02 % |
2,076 |
|
4. To re-elect as a Director Mr D Mackney |
79,945,159 |
99.99 % |
3,035 |
0.01 % |
2,152 |
|
5. To re-appoint PricewaterhouseCoopers LLP as auditors and to authorise the Directors to determine their remuneration |
79,944,302 |
99.99 % |
5,393 |
0.01 % |
651 |
|
6. To authorise the Directors to allot shares |
79,942,875 |
99.99 % |
4,769 |
0.01 % |
2,702 |
|
Special Resolutions (requires 75% majority) |
|||||
|
7. To authorise the Directors to disapply pre-emption rights |
79,939,633 |
99.99 % |
7,923 |
0.01 % |
2,790 |
|
8. To reduce the notice period for general meetings |
79,942,423 |
99.99 % |
5,331 |
0.01 % |
2,592 |
|
9. To adopt new articles of Association of the Company |
79,942,176 |
99.99 % |
4,233 |
0.01 % |
3,937 |
*NB: Percentage of votes cast excludes withheld votes
Β
The Company confirms that two copies of all resolutions passed at the Annual General Meeting held earlier today, Tuesday 1 June 2010, will be forwarded to the UK Listing Authority's Document Viewing Facility later today. These copies will be available for viewing at the Document Viewing Facility, at the address below, from 9.00am to 5.30pm on every weekday except bank holidays.
Β
The Document Viewing Facility is situated at:
Β
25 The North Colonnade
Canary Wharf
London
E14 5HS
Β
Β
Β
- ends -
Β
Enquiries:
Β
|
Vernalis |
+44 (0) 118 989 9360 |
|
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer Β |
|
|
Brunswick Group |
+44 (0) 20 7404 5959 |
|
Jon Coles Justine McIlroy Will Carnwath Β |
|
|
Taylor Rafferty |
+44 (0) 20 7614 2900 |
|
Rob Newman Faisal Kanth |
|
Β
About Vernalis:
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eleven candidates in development, eight of which are designated priority programmes. Five of these priority programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Biogen Idec, Chiesi, Endo, GSK, Menarini, Novartis and Servier.
Β
For further information about Vernalis, please visit www.vernalis.com.
Β
Β
Follow the stocks
